{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:11:26Z","timestamp":1793214686828,"version":"4.5.0"},"reference-count":170,"publisher":"Rockefeller University Press","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/rupress.org\/pages\/terms102024\/"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PF-24-1320972- 01-ET"],"award-info":[{"award-number":["PF-24-1320972- 01-ET"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:p>Conventional type 1 dendritic cells (cDC1s) promote antitumor immunity through efficient cross-presentation of tumor antigens and production of key mediators. Crucially, in the tumor microenvironment, cDC1s orchestrate immune hubs and signaling axes that support T cell responses and are associated with improved patient outcomes. During tumor progression, however, cDC1 activity is increasingly constrained by immunosuppressive signals and inhibitory cellular interactions. Many immunotherapies, including immune checkpoint blockade and adoptive cell transfer, depend on functional cDC1 populations for optimal efficacy, underscoring the need to define both the mechanisms that enable cDC1-mediated immunity and those that suppress it. Emerging strategies aim to harness cDC1s by expanding their numbers, reprogramming suppressed DC states, or strengthening interactions with CD8+ and CD4+ T cells and natural killer cells. Here, we discuss the molecular pathways, cellular phenotypes, and spatial features that govern cDC1 function, highlight the prognostic and predictive value of cDC1-associated signatures, and evaluate therapeutic approaches that leverage cDC1 biology to improve cancer treatment and durability of response.<\/jats:p>","DOI":"10.1084\/jem.20241199","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:21:04Z","timestamp":1778826064000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Leveraging cDC1 biology and function for enhanced immunotherapy"],"prefix":"10.1084","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-4022","authenticated-orcid":true,"given":"Ross W.","family":"Ward","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai 1 Division of Hematology & Medical Oncology, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-8720","authenticated-orcid":true,"given":"Uddipan","family":"Kar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai 1 Division of Hematology & Medical Oncology, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2092-5145","authenticated-orcid":true,"given":"Sreekumar","family":"Balan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai 1 Division of Hematology & Medical Oncology, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-4187","authenticated-orcid":true,"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai 1 Division of Hematology & Medical Oncology, , New York, NY,","place":["USA"]},{"id":[{"id":"https:\/\/ror.org\/0184qbg02","id-type":"ROR","asserted-by":"publisher"}],"name":"Parker Institute for Cancer Immunotherapy 2 , San Francisco, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026061010022269700_bib1","doi-asserted-by":"publisher","first-page":"A1047","DOI":"10.1136\/jitc-2024-009588","article-title":"Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy","volume":"12","author":"Acero-Bedoya","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70079","article-title":"Identity, functions, and the spatiotemporal maturation of type 1 conventional dendritic cells","volume":"336","author":"Akyol","year":"2025","journal-title":"Immunol. Rev."},{"key":"2026061010022269700_bib3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/2326-6066.CIR-24-1259","article-title":"IL2\/IL15 signaling induces NK cell production of FLT3LG, augmenting anti\u2013PD-1 immunotherapy","volume":"14","author":"Avanessian","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"2026061010022269700_bib4","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.celrep.2018.07.033","article-title":"Large-scale human dendritic cell differentiation revealing notch-dependent lineage bifurcation and heterogeneity","volume":"24","author":"Balan","year":"2018","journal-title":"Cell Rep."},{"key":"2026061010022269700_bib5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.07.004","article-title":"Dendritic cell subsets and locations","volume":"348","author":"Balan","year":"2019","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"2026061010022269700_bib6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1158\/2326-6066.CIR-25-0034","article-title":"Harnessing notch signaling to enhance the generation and functionality of human conventional type 1 dendritic cells for cancer immunotherapy applications","volume":"13","author":"Balan","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"2026061010022269700_bib7","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer\u2013dendritic cell axis defines checkpoint therapy\u2013responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"key":"2026061010022269700_bib8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41590-024-02065-8","article-title":"Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer","volume":"26","author":"Belabed","year":"2025","journal-title":"Nat. Immunol."},{"key":"2026061010022269700_bib9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11912-023-01392-7","article-title":"AXL inhibitors: Status of clinical development","volume":"25","author":"Bhalla","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"2026061010022269700_bib10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-020-00143-y","article-title":"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat. Cancer"},{"key":"2026061010022269700_bib11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"2026061010022269700_bib12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib13","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep."},{"key":"2026061010022269700_bib14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41590-020-00824-x","article-title":"The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens","volume":"22","author":"Canton","year":"2021","journal-title":"Nat. Immunol."},{"key":"2026061010022269700_bib15","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.19.654765","article-title":"Intratumoral cDC1-T cell clusters serve as sites of local costimulation to enhance CTL-mediated tumor rejection","author":"Carbone","year":"2025","journal-title":"bioRxiv"},{"key":"2026061010022269700_bib16","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1038\/s41467-022-34897-z","article-title":"The circadian clock influences T cell responses to vaccination by regulating dendritic cell antigen processing","volume":"13","author":"Cervantes-Silva","year":"2022","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib17","doi-asserted-by":"publisher","first-page":"115023","DOI":"10.1016\/J.CELREP.2024.115023","article-title":"Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells","volume":"43","author":"Chun","year":"2024","journal-title":"Cell Rep."},{"key":"2026061010022269700_bib18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: An update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"key":"2026061010022269700_bib19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-003351","article-title":"Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants","volume":"9","author":"Conde","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002054","article-title":"DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type i conventional dendritic cells","volume":"9","author":"Cueto","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aal1713","article-title":"Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells","volume":"2","author":"Dai","year":"2017","journal-title":"Sci. Immunol."},{"key":"2026061010022269700_bib22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1108003","article-title":"Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate","volume":"307","author":"Delamarre","year":"2005","journal-title":"Science"},{"key":"2026061010022269700_bib23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008739","article-title":"TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response","volume":"12","author":"De Le\u00f3n-Rodr\u00edguez","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib24","doi-asserted-by":"publisher","first-page":"232ra51","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2026061010022269700_bib25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301339","article-title":"Biomaterials facilitating dendritic cell-mediated cancer immunotherapy","volume":"10","author":"Dong","year":"2023","journal-title":"Adv. Sci."},{"key":"2026061010022269700_bib26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.immuni.2016.10.010","article-title":"Functions of murine dendritic cells","volume":"45","author":"Durai","year":"2016","journal-title":"Immunity"},{"key":"2026061010022269700_bib27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","article-title":"Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors","volume":"42","author":"Espinosa-Carrasco","year":"2024","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"2026061010022269700_bib29","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/2326-6066.CIR-21-0865","article-title":"cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1","volume":"10","author":"Ferris","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"2026061010022269700_bib30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"2026061010022269700_bib31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200264","article-title":"Tumor-infiltrating dendritic cell states are conserved across solid human cancers","volume":"218","author":"Gerhard","year":"2021","journal-title":"J. Exp. Med."},{"key":"2026061010022269700_bib32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat. Cancer"},{"key":"2026061010022269700_bib33","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.1038\/s41467-025-64172-w","article-title":"Dendritic cell progenitors engineered to express extracellular-vesicle\u2013internalizing receptors enhance cancer immunotherapy in mouse models","volume":"16","author":"Ghasemi","year":"2025","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.abg3570","article-title":"NF-\u03baB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity","volume":"6","author":"Ghislat","year":"2021","journal-title":"Sci. Immunol."},{"key":"2026061010022269700_bib35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","article-title":"The spatial organization of cDC1 with CD8+ T cells is critical for the response to immune checkpoint inhibitors in patients with melanoma","volume":"13","author":"Gobbini","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"2026061010022269700_bib36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccr.2011.01.037","article-title":"Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory TH2 cells via an IL-12- and OX40L-dependent pathway","volume":"19","author":"Godefroy","year":"2011","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib37","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase i study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann. Oncol."},{"key":"2026061010022269700_bib38","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s43018-023-00620-0","article-title":"Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade","volume":"4","author":"Goswami","year":"2023","journal-title":"Nat. Cancer"},{"key":"2026061010022269700_bib39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"2026061010022269700_bib40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.01267","article-title":"The superior ability of human BDCA3+ (CD141+) dendritic cells (DCs) to cross-present antigens derived from necrotic lung cancer cells","volume":"11","author":"Gu","year":"2020","journal-title":"Front. Immunol."},{"key":"2026061010022269700_bib41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: A unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"2026061010022269700_bib42","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat. Med."},{"key":"2026061010022269700_bib43","doi-asserted-by":"publisher","first-page":"4468145","DOI":"10.1155\/2024\/4468145","article-title":"Characterizing the tumor microenvironment and its correlation with cDC1-related gene expression in gastric cancer","volume":"2024","author":"Han","year":"2024","journal-title":"J. Immunol. Res."},{"key":"2026061010022269700_bib44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026061010022269700_bib45","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/s41467-025-58289-1","article-title":"Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse","volume":"16","author":"Heras-Murillo","year":"2025","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib46","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8 + dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"2026061010022269700_bib47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.adp3978","article-title":"Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer","volume":"10","author":"Hogg","year":"2025","journal-title":"Sci. Immunol."},{"key":"2026061010022269700_bib48","doi-asserted-by":"publisher","first-page":"113684","DOI":"10.1016\/j.jconrel.2025.113684","article-title":"Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L\/Flt3L mRNA-mediated dendritic cell activation","volume":"382","author":"Hou","year":"2025","journal-title":"J. Control Release"},{"key":"2026061010022269700_bib49","doi-asserted-by":"publisher","DOI":"10.1126\/SCIIMMUNOL.AAV3942","article-title":"IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer","volume":"5","author":"Hubert","year":"2020","journal-title":"Sci. Immunol."},{"key":"2026061010022269700_bib50","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"2026061010022269700_bib51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41541-025-01084-2","article-title":"Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials","volume":"10","author":"Hussain","year":"2025","journal-title":"Npj Vaccin."},{"key":"2026061010022269700_bib52","doi-asserted-by":"publisher","first-page":"TPS2697","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2697","article-title":"A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors","volume":"42","author":"Ito","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026061010022269700_bib53","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145885","article-title":"Type 2 dendritic cells mediate control of cytotoxic t cell resistant tumors","volume":"6","author":"Iwanowycz","year":"2021","journal-title":"JCI Insight"},{"key":"2026061010022269700_bib54","doi-asserted-by":"publisher","first-page":"1087843","DOI":"10.3389\/fimmu.2022.1087843","article-title":"Single-cell analysis of myeloid cells in HPV+ tonsillar cancer","volume":"13","author":"Jimenez","year":"2023","journal-title":"Front. Immunol."},{"key":"2026061010022269700_bib55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn6612","article-title":"Selective STING stimulation in dendritic cells primes antitumor T cell responses","volume":"8","author":"Jneid","year":"2023","journal-title":"Sci. Immunol."},{"key":"2026061010022269700_bib56","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J. Exp. Med."},{"key":"2026061010022269700_bib57","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/ijc.34874","article-title":"Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells","volume":"154","author":"Kamei","year":"2024","journal-title":"Int. J. Cancer"},{"key":"2026061010022269700_bib58","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"2026061010022269700_bib59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114282119","article-title":"CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory","volume":"119","author":"Kidani","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026061010022269700_bib60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2025-102184","article-title":"NEOadjuvant dendritic cell therapy added to first line standard of care in advanced epithelial ovarian cancer (NEODOC): Protocol of a first-in-human, exploratory, single-centre phase I\/II trial in the Netherlands","volume":"15","author":"Koeneman","year":"2025","journal-title":"BMJ Open"},{"key":"2026061010022269700_bib61","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/0008-5472.CAN-11-0291","article-title":"FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines","volume":"71","author":"Kreiter","year":"2011","journal-title":"Cancer Res."},{"key":"2026061010022269700_bib62","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1038\/s41467-020-19833-3","article-title":"CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function","volume":"11","author":"Kuhn","year":"2020","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: Myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Kurt","year":"2023","journal-title":"J. Clin. Invest."},{"key":"2026061010022269700_bib64","doi-asserted-by":"publisher","first-page":"1873056","DOI":"10.1080\/21645515.2021.1873056","article-title":"Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A","volume":"18","author":"Lahoud","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"2026061010022269700_bib65","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat. Immunol."},{"key":"2026061010022269700_bib66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171621","article-title":"In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy","volume":"134","author":"Lam","year":"2024","journal-title":"J. Clin. Invest."},{"key":"2026061010022269700_bib67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","article-title":"An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis","volume":"625","author":"LaMarche","year":"2024","journal-title":"Nature"},{"key":"2026061010022269700_bib68","doi-asserted-by":"publisher","first-page":"13720","DOI":"10.1038\/ncomms13720","article-title":"The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity","volume":"7","author":"Laoui","year":"2016","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib69","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1084\/jem.20092720","article-title":"Mouse CD8\u03b1+ DCs and human BDCA3+ DCs are major producers of IFN-\u03bb in response to poly IC","volume":"207","author":"Lauterbach","year":"2010","journal-title":"J. Exp. Med."},{"key":"2026061010022269700_bib71","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41467-024-44787-1","article-title":"Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib170","doi-asserted-by":"publisher","first-page":"9092","DOI":"10.1038\/s41467-024-53347-6","article-title":"Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-001963","article-title":"Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-022-35615-5","article-title":"CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment","volume":"14","author":"Lei","year":"2023","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib73","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41423-024-01133-1","article-title":"CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors","volume":"21","author":"Lei","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"2026061010022269700_bib74","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1199","article-title":"Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"2026061010022269700_bib75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010581","article-title":"XCL1-secreting CEA CAR-T cells enhance endogenous CD8+ T cell responses to tumor neoantigens to confer a long-term antitumor immunity","volume":"13","author":"Li","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib76","doi-asserted-by":"publisher","first-page":"101479","DOI":"10.1016\/j.xcrm.2024.101479","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2026061010022269700_bib77","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1546068","article-title":"Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"key":"2026061010022269700_bib78","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.1038\/s41467-022-34495-z","article-title":"Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib79","doi-asserted-by":"publisher","DOI":"10.64898\/2026.01.14.699162","article-title":"Scalable generation of clinical-grade universal human cDC1s enables potent antitumor immunotherapy","author":"Liu","year":"2026","journal-title":"bioRxiv"},{"key":"2026061010022269700_bib80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41467-024-46685-y","article-title":"Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors","volume":"15","author":"L\u00f3pez","year":"2024","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib81","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: Therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"2026061010022269700_bib82","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026061010022269700_bib83","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","article-title":"Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing","volume":"55","author":"MacNabb","year":"2022","journal-title":"Immunity"},{"key":"2026061010022269700_bib84","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat. Med."},{"key":"2026061010022269700_bib85","doi-asserted-by":"publisher","DOI":"10.1126\/science.adh4567","article-title":"Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer","volume":"384","author":"Mahadevan","year":"2024","journal-title":"Science"},{"key":"2026061010022269700_bib86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"2026061010022269700_bib87","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"2026061010022269700_bib88","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1200\/JCO-24-02595","article-title":"BO-112 plus pembrolizumab for patients with anti-PD-1-resistant advanced melanoma: Phase II clinical trial SPOTLIGHT-203","volume":"43","author":"M\u00e1rquez-Rodas","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026061010022269700_bib171","first-page":"A623","article-title":"595 Flt3L-primed in situ vaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and ER\/PR+ breast cancer.","volume":"10","author":"Marron","year":"2022","journal-title":"J. Immuno Ther. Cancer."},{"key":"2026061010022269700_bib90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejca.2020.04.036","article-title":"Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer","volume":"135","author":"Mastelic-Gavillet","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"2026061010022269700_bib91","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.3389\/fimmu.2018.02775","article-title":"A highly active form of XCL1\/lymphotactin functions as an effective adjuvant to recruit cross-presenting dendritic cells for induction of effector and memory CD8+ T cells","volume":"9","author":"Matsuo","year":"2018","journal-title":"Front. Immunol."},{"key":"2026061010022269700_bib92","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3389\/fimmu.2018.02805","article-title":"Novel cre-expressing mouse strains permitting to selectively track and edit type 1 conventional dendritic cells facilitate disentangling their complexity in vivo","volume":"9","author":"Mattiuz","year":"2018","journal-title":"Front. Immunol."},{"key":"2026061010022269700_bib93","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1305","article-title":"Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T-cell protective responses to breast cancer","volume":"10","author":"Mattiuz","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"2026061010022269700_bib94","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.27.628014","article-title":"Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer","author":"Mattiuz","year":"2024","journal-title":"bioRxiv"},{"key":"2026061010022269700_bib95","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","article-title":"A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity","volume":"41","author":"Meiser","year":"2023","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib96","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.1038\/s41467-020-19781-y","article-title":"Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma","volume":"11","author":"Melaiu","year":"2020","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib97","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41590-018-0145-8","article-title":"Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific","volume":"19","author":"Michea","year":"2018","journal-title":"Nat. Immunol."},{"key":"2026061010022269700_bib98","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155022","article-title":"CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity","volume":"7","author":"Modak","year":"2022","journal-title":"JCI Insight"},{"key":"2026061010022269700_bib99","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41568-024-00787-3","article-title":"Dendritic cell maturation in cancer","volume":"25","author":"Moon","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026061010022269700_bib100","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"key":"2026061010022269700_bib101","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2326-6066.CIR-24-0324","article-title":"Combination CXCR4 and PD-1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma","volume":"13","author":"Morita","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"2026061010022269700_bib102","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026061010022269700_bib103","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144913","article-title":"MMP2 and TLRs modulate immune responses in the tumor microenvironment","volume":"6","author":"Muniz-Bongers","year":"2021","journal-title":"JCI Insight"},{"key":"2026061010022269700_bib104","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70081","article-title":"The making of a cDC1: Precision programming of progenitor potential","volume":"337","author":"Murphy","year":"2026","journal-title":"Immunol. Rev."},{"key":"2026061010022269700_bib105","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1021\/acscentsci.3c01310","article-title":"Mannosylated STING agonist drugamers for dendritic cell-mediated cancer immunotherapy","volume":"10","author":"Nguyen","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"2026061010022269700_bib106","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1038\/s41467-020-19192-z","article-title":"Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s","volume":"11","author":"Oba","year":"2020","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib107","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Cancer"},{"key":"2026061010022269700_bib108","doi-asserted-by":"publisher","first-page":"111201","DOI":"10.1016\/j.celrep.2022.111201","article-title":"Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment","volume":"40","author":"Papadas","year":"2022","journal-title":"Cell Rep."},{"key":"2026061010022269700_bib109","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib110","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70011","article-title":"Spatial organisation of tumour cDC1 states correlates with effector and stem-like CD8+ T cells location","volume":"55","author":"Piot","year":"2025","journal-title":"Eur. J. Immunol."},{"key":"2026061010022269700_bib111","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/cancers14051216","article-title":"Clinical significance of tumor-infiltrating conventional and plasmacytoid dendritic cells in pancreatic ductal adenocarcinoma","volume":"14","author":"Plesca","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026061010022269700_bib112","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1073\/pnas.2519922122","article-title":"WDFY4-dependent cross-presentation proceeds via a vacuolar antigen-processing route","volume":"122","author":"Postoak","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026061010022269700_bib113","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1158\/1538-7445.AM2022-4197","article-title":"Abstract 4197: Treatment with chemotherapy, CD40 agonist, and Flt3 ligand triplet combination enhances antigen presentation and leads to cures in triple negative breast cancer","volume":"82","author":"Ramani","year":"2022","journal-title":"Cancer Res."},{"key":"2026061010022269700_bib114","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240957","article-title":"Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis","volume":"222","author":"Ray","year":"2025","journal-title":"J. Exp. Med."},{"key":"2026061010022269700_bib115","doi-asserted-by":"publisher","first-page":"OT2-17-01","DOI":"10.1158\/1538-7445.SABCS22-OT2-17-01","article-title":"Abstract OT2-17-01: Phase 1 trial of anthracycline chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer","volume":"83","author":"Reddy","year":"2023","journal-title":"Cancer Res."},{"key":"2026061010022269700_bib116","doi-asserted-by":"publisher","first-page":"101256","DOI":"10.1016\/j.xcrm.2023.101256","article-title":"FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis","volume":"4","author":"R\u00e9gnier","year":"2023","journal-title":"Cell Rep. Med."},{"key":"2026061010022269700_bib117","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib118","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005011","article-title":"Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control","volume":"11","author":"Rodriguez-Ruiz","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib119","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10238-024-01362-8","article-title":"Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody","volume":"24","author":"Roider","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"2026061010022269700_bib120","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-19-3826","article-title":"Adenocarcinoma of the uterine cervix shows impaired recruitment of cDC1 and CD8+ T cells and elevated \u03b2-catenin activation compared with squamous cell carcinoma","volume":"26","author":"Rotman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026061010022269700_bib121","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","article-title":"Visualizing synaptic transfer of tumor antigens among dendritic cells","volume":"37","author":"Ruhland","year":"2020","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-31941-w","article-title":"Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC","volume":"13","author":"Saddawi-Konefka","year":"2022","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib123","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1158\/1078-0432.CCR-23-3477","article-title":"Targeting dendritic cell dysfunction to circumvent anti-PD1 resistance in head and neck cancer","volume":"30","author":"Saito","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2026061010022269700_bib124","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"2026061010022269700_bib125","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","article-title":"Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting","volume":"3","author":"Salomon","year":"2022","journal-title":"Nat. Cancer"},{"key":"2026061010022269700_bib126","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti\u2013PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov."},{"key":"2026061010022269700_bib127","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","article-title":"Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity","volume":"25","author":"Santollani","year":"2024","journal-title":"Nat. Immunol."},{"key":"2026061010022269700_bib128","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.immuni.2009.01.013","article-title":"The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8+ dendritic cells","volume":"30","author":"Savina","year":"2009","journal-title":"Immunity"},{"key":"2026061010022269700_bib129","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","article-title":"Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes","volume":"54","author":"Schenkel","year":"2021","journal-title":"Immunity"},{"key":"2026061010022269700_bib130","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1084\/jem.20021263","article-title":"ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8\u03b1+ dendritic cells","volume":"196","author":"Schiavoni","year":"2002","journal-title":"J. Exp. Med."},{"key":"2026061010022269700_bib131","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"key":"2026061010022269700_bib132","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1190","article-title":"BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients","volume":"9","author":"Sosa Cuevas","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"2026061010022269700_bib133","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"2026061010022269700_bib134","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib135","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41586-024-07752-y","article-title":"Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy","volume":"632","author":"Sultan","year":"2024","journal-title":"Nature"},{"key":"2026061010022269700_bib136","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1038\/s41467-022-34791-8","article-title":"Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity","volume":"13","author":"Svensson-Arvelund","year":"2022","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib137","doi-asserted-by":"publisher","first-page":"1085547","DOI":"10.3389\/fimmu.2023.1085547","article-title":"IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma","volume":"14","author":"Swan","year":"2023","journal-title":"Front. Immunol."},{"key":"2026061010022269700_bib138","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-025-09202-9","article-title":"Rescuing dendritic cell interstitial motility sustains antitumour immunity","volume":"645","author":"Tang","year":"2025","journal-title":"Nature"},{"key":"2026061010022269700_bib139","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib140","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-22-1046","article-title":"Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy","volume":"82","author":"Teijeira","year":"2022","journal-title":"Cancer Res."},{"key":"2026061010022269700_bib141","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1126\/science.aat5030","article-title":"WDFY4 is required for cross-presentation in response to viral and tumor antigens","volume":"362","author":"Theisen","year":"2018","journal-title":"Science"},{"key":"2026061010022269700_bib142","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1126\/science.1080106","article-title":"Activation of lysosomal function during dendritic cell maturation","volume":"299","author":"Trombetta","year":"2003","journal-title":"Science"},{"key":"2026061010022269700_bib143","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.4049\/jimmunol.1000808","article-title":"Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity","volume":"186","author":"Tsuji","year":"2011","journal-title":"J. Immunol."},{"key":"2026061010022269700_bib144","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12929-024-01006-9","article-title":"FLT3L-induced virtual memory CD8 T cells engage the immune system against tumors","volume":"31","author":"Tu","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"2026061010022269700_bib145","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-023-01908-6","article-title":"A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state","volume":"22","author":"Van Lint","year":"2023","journal-title":"Mol. Cancer"},{"key":"2026061010022269700_bib146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002569","article-title":"Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib147","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","article-title":"Dendritic cells direct circadian anti-tumour immune responses","volume":"614","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"2026061010022269700_bib148","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"2026061010022269700_bib149","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj3945","article-title":"STING licensing of type I dendritic cells potentiates antitumor immunity","volume":"9","author":"Wang","year":"2024","journal-title":"Sci. Immunol."},{"key":"2026061010022269700_bib150","doi-asserted-by":"publisher","first-page":"108896","DOI":"10.1016\/j.isci.2024.108896","article-title":"Single-cell transcriptomics reveals the role of antigen presentation in liver metastatic breast cancer","volume":"27","author":"Wang","year":"2024","journal-title":"iScience"},{"key":"2026061010022269700_bib151","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011665","article-title":"In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib152","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40425-019-0565-5","article-title":"Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen","volume":"7","author":"Wculek","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib153","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1101504","article-title":"Conventional dendritic cells require IRAP-Rab14 endosomes for efficient cross-presentation","volume":"188","author":"Weimershaus","year":"2012","journal-title":"J. Immunol."},{"key":"2026061010022269700_bib154","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41590-022-01324-w","article-title":"Mechanisms of CD40-dependent cDC1 licensing beyond costimulation","volume":"23","author":"Wu","year":"2022","journal-title":"Nat. Immunol."},{"key":"2026061010022269700_bib155","doi-asserted-by":"publisher","first-page":"102307","DOI":"10.1016\/j.xcrm.2025.102307","article-title":"Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity","volume":"6","author":"Xiao","year":"2025","journal-title":"Cell Rep. Med."},{"key":"2026061010022269700_bib156","doi-asserted-by":"publisher","DOI":"10.1126\/science.ady5362","article-title":"Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity","volume":"390","author":"Xie","year":"2025","journal-title":"Science"},{"key":"2026061010022269700_bib157","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s12276-023-01080-3","article-title":"Drug conjugates for targeting regulatory T cells in the tumor microenvironment: Guided missiles for cancer treatment","volume":"55","author":"Yang","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"2026061010022269700_bib158","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1038\/s41467-025-62878-5","article-title":"Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma","volume":"16","author":"Yang","year":"2025","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib159","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","article-title":"Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity","volume":"42","author":"You","year":"2024","journal-title":"Cancer Cell"},{"key":"2026061010022269700_bib160","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.immuni.2023.01.010","article-title":"Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer","volume":"56","author":"Zagorulya","year":"2023","journal-title":"Immunity"},{"key":"2026061010022269700_bib161","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1172\/JCI60644","article-title":"The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice","volume":"122","author":"Zelenay","year":"2012","journal-title":"J. Clin. Invest."},{"key":"2026061010022269700_bib162","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41420-024-01960-1","article-title":"Circadian rhythm regulates the function of immune cells and participates in the development of tumors","volume":"10","author":"Zeng","year":"2024","journal-title":"Cell Death Discov."},{"key":"2026061010022269700_bib163","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.immuni.2012.03.009","article-title":"The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments","volume":"36","author":"Zhang","year":"2012","journal-title":"Immunity"},{"key":"2026061010022269700_bib164","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.1038\/s41467-020-19973-6","article-title":"CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"2026061010022269700_bib165","doi-asserted-by":"publisher","first-page":"108381","DOI":"10.1016\/j.celrep.2020.108381","article-title":"Inflammasomes within hyperactive murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity","volume":"33","author":"Zhivaki","year":"2020","journal-title":"Cell Rep."},{"key":"2026061010022269700_bib166","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1016\/j.cell.2024.05.026","article-title":"Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors","volume":"187","author":"Zhivaki","year":"2024","journal-title":"Cell"},{"key":"2026061010022269700_bib167","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 + conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"2026061010022269700_bib168","doi-asserted-by":"publisher","first-page":"114141","DOI":"10.1016\/j.celrep.2024.114141","article-title":"Batf3+ DCs and the 4-1BB\/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1\/PD-L1 blockade efficacy","volume":"43","author":"Ziblat","year":"2024","journal-title":"Cell Rep."},{"key":"2026061010022269700_bib169","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2025.11.020","article-title":"Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity","volume":"59","author":"Zitti","year":"2025","journal-title":"Immunity"}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20241199\/2036363\/jem_20241199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20241199\/2036363\/jem_20241199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:02:31Z","timestamp":1781100151000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/223\/7\/e20241199\/282725\/Leveraging-cDC1-biology-and-function-for-enhanced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":170,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20241199","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"e20241199"}}